Precision BioSciences, Inc. (DTIL)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Michael Amoroso
|
President, CEO & Director | 1.16M | -- | 1978 |
|
Mr. John Alexander Kelly R.Ph.
|
Chief Operating Officer | 717.06k | -- | 1967 |
|
Mr. Dario Scimeca J.D.
|
Chief Legal Officer & Secretary | 659.64k | -- | 1975 |
|
Dr. Jefferson J. Smith Ph.D.
|
Co-Founder & Chief Research Officer | 640.2k | -- | 1973 |
|
Mr. Naresh Tanna
|
Chief Financial Officer | -- | -- | 1981 |
|
Ms. Mei Burris
|
VP of Finance & Chief Accounting Officer | -- | -- | 1986 |
|
Dr. Cassie Gorsuch Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Ms. Juli Blanche
|
Chief People Officer | -- | -- | -- |
|
Ms. Cindy Atwell
|
Chief Development Officer | -- | -- | -- |
|
Mr. Neil Leatherbury M.S.
|
Senior VP and Head of Chemistry, Manufacturing & Controls | -- | -- | -- |
Precision BioSciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 67
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Corporate Governance
Upcoming Events
November 3, 2026 at 12:30 PM UTC
Precision BioSciences, Inc. Earnings Date
